US 7727525
Engineered anti-CD20 antibody fragments for in vivo targeting and therapeutics
granted A61KA61K51/1027A61P
Quick answer
US patent 7727525 (Engineered anti-CD20 antibody fragments for in vivo targeting and therapeutics) held by The Regents of the University of California expires Mon May 27 2030 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- The Regents of the University of California
- Grant date
- Tue Jun 01 2010 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon May 27 2030 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 5
- CPC classes
- A61K, A61K51/1027, A61P, A61P37/00